Table I.

Clinical trials of MSCs in respiratory diseases.

Study (year)	Disease/Condition	Cell Type	Delivery Route	Primary Endpoint	Refs.
Ribeiro-Paes et al (2011)	Advanced COPD	BMMC	IV	Safety of SC infusion	(36)
Weiss et al (2013)	Moderate to severe COPD	BM-MSCs	IV	Safety of systemic MSC administration
Tzouvelekis et al (2013)	Mild to moderate IPF	ADSCs-SVF	EB	Safety (incidence of treatment emergent adverse events)	(19)
Zheng et al (2014)	ARDS	AD-MSCs	IV	Safety (possible adverse events after systemic administration of AD-MSCs)	(29)
Chambers et al (2014)	Moderate IPF	PD-MSCs	IV	Safety and feasibility of an infusion of PD-MSCs	(20)
Wilson et al (2015)	Moderate to severe ARDS	BM-MSCs	IV	Safety of BM MSCs intravenous infusion	(28)
Baughman et al (2015)	Advanced Pulmonary Sarcoidosis	PD-MCs	IV	Acute effect of cell therapy on pulmonary artery pressure	(37)
Stolk et al (2016)	Severe emphysema	BM-MSCs	IV	Safety and feasibility of IV administration of BM-MScs	(33)
Glassberg et al (2017)	Mild to moderate IPF	BM-MSCs	IV	Safety of a single infusion of BM-MSCs	(21)

BMMC, bone marrow mononuclear cells; IV, intravenously; SC, stem cell; BM-MSCs, bone marrow derived mesenchymal stem cells; ADSCs-SVF, adipose derived stem cells-stromal vascular factor; Endobronchially; AD-MSCs, adipose derived-mesenchymal stem cells; PD-MSCs, placenta derived-mesenchymal stem cells; PD-MCs, placenta derived-mesenchymal-like cells.